Triptorelin

13,14-dihydro PGE1 is a biologically active metabolite of PGE1 with comparable potency to the parent compound. It is an inhibitor of ADP-induced platelet aggregation in human PRP and washed platelets with IC50 values of 31 and 21 nM, respectively.

A cell-permeable, selective inhibitor of N-WASP (IC₅₀ = ~ 10 &muM) directly associates with the GTPase-binding domain of N-WASP, preventing its activation by Cdc42 and PIP2 interferes with membrane transport, endocytosis, and

An isomer of 17-phenyl trinor PGF2&alpha ethyl amide, characterized by an inverted (&beta) hydroxyl group at C-15.

A stable analog of PGF2&alpha 2-glyceryl ester incorporating an activity-enhancing 17-phenyl substitution.

A lipophilic analog of 17-phenyl trinor PGF2&alpha, a potent agonist for the FP receptor.

17-phenyl trinor-13,14-dihydro PGA2 is a synthetic PG analog whose biological activity has not been widely reported. The PGF2&alpha analog latanoprost, which bears the same lower side chain features, has been approved as a pharmaceutical for the

A synthetic analog of PGA2 with structural features similar to 15-deoxy-&Delta12,14-PGJ2, a ligand for PPAR&gamma.

A lipophilic analog of 17-phenyl trinor PGF2&alpha, a potent agonist for the FP receptor.

A novel analog of 17-phenyl trinor PGF2&alpha ethyl amide.

16,16-dimethyl PGE1 is a metabolically stable synthetic analog of PGE1. It induces human vascular smooth muscle contractions in vitro.

A latanoprost-related isomer containing both a double bond at C-13,14 and an invered (b) hydroxyl group at C-15 a potential impurity in most commercial preparations of the lantanoprost bulk drug product.

An isopropyl ester of the free acid PG which corresponds to bimatoprost a potent ocular hypotensive agent, lowering the IOP 1.3 mm Hg below the level achieved by latanoprost, but with significantly more irritation.